A recepção da família na hospitalização de crianças

Fundamentando-se em estudos que discutem a participação de familiares na hospitalização de seus filhos, este trabalho pretende estudar como os familiares de crianças hospitalizadas vivenciam o momento da recepção, que profissional da equipe os acompanha durante os procedimentos iniciais, que informações recebem e quem encarrega-se de informá-los, logo que a criança é admitida no hospital em razão de uma doença que necessita de cuidados hospitalares. Os participantes foram 40 pais e se utilizou entrevistas semi-estruturadas para a coleta de dados. Estes foram analisados segundo métodos de análise de conteúdo. Os resultados mostraram que os pais vivenciam um estado de ansiedade generalizado, não sabem nomear que profissional os acompanhou, além de lembrarem-se de informações esporádicas que dizem respeito, exclusivamente, às suas necessidades imediatas

Sadržaj

The self-diffusion phenomenon in a two-dimensional dusty plasma at extremely strong (effective) magnetic fields is studied experimentally and by means of molecular dynamics simulations. In the experiment the high magnetic field is introduced by rotating the particle cloud and observing the particle trajectories in a co-rotating frame, which allows reaching effective magnetic fields up to 3000 Tesla. The experimental results confirm the predictions of the simulations: (i) super-diffusive behavior is found at intermediate time-scales and (ii) the dependence of the self-diffusion coefficient on the magnetic field is well reproduced.Comment: accepted by Physical Review

GABA Receptors and the Pharmacology of Sleep

Current GABAergic sleep-promoting medications were developed pragmatically, without making use of the immense diversity of GABAA receptors. Pharmacogenetic experiments are leading to an understanding of the circuit mechanisms in the hypothalamus by which zolpidem and similar compounds induce sleep at α2βγ2-type GABAA receptors. Drugs acting at more selective receptor types, for example, at receptors containing the α2 and/or α3 subunits expressed in hypothalamic and brain stem areas, could in principle be useful as hypnotics/anxiolytics. A highly promising sleep-promoting drug, gaboxadol, which activates αβδ-type receptors failed in clinical trials. Thus, for the time being, drugs such as zolpidem, which work as positive allosteric modulators at GABAA receptors, continue to be some of the most effective compounds to treat primary insomnia

Effects of bismuth oxide on the sinterability of hydroxyapatite

The sinterability of Bi2O3-doped hydroxyapatite (HA) has been studied and compared with the undoped HA. Varying amounts of Bi2O3 ranging from 0.05 wt% to 1.0 wt% were mixed with the HA. The study revealed that most sintered samples composed of the HA phase except for compacts containing 0.3, 0.5 and 1.0 wt% Bi2O3 and when sintered above 1100 8C, 1000 8C and 950 8C, respectively. In general, the addition of 0.5 wt% Bi2O3 was identified as the optimum amount to promote densification as well as to improve the mechanical properties of sintered HA at low temperature of 1000 8C. Throughout the sintering regime, the highest value of relative bulk density of 98.7% was obtained for 0.5 wt% Bi2O3-doped HA when sintered at 1000 8C. A maximum Young’s modulus of 119.2 GPa was measured for 0.1 wt% Bi2O3-doped HA when sintered at 1150 8C. Additionally, the ceramic was able to achieve highest hardness of 6.08 GPa and fracture toughness of 1.21 MPa m1/2 at sintering temperature of 1000 8C

Sintering of hydroxyapatite ceramic produced by wet chemical method

In the present work, densification of synthesised hydroxyapatite (HA) bioceramic prepared via chemical precipitation method was investigated. HA samples was prepared by compaction at 200 MPa and sintered at temperatures ranging from 800°C to 1400°C. The results revealed that the HA phase was stable for up to sintering temperature of 1250°C. However, decomposition of HA was observed in samples sintered at 1300°C with the formation of tetra-calcium phosphate (TTCP) and CaO. Samples sintered above 1400°C were found to melt into glassy phases. The bulk density increases with increasing temperature and attained a maximum value of 3.14 gcm-3 at 1150°C whereas maximum hardness value of 6.64 GPa was measured in HA sintered at 1050°C. These results are discussed in terms of the role of grain size. © (2011) Trans Tech Publications, Switzerland

Effects of powder synthesis method on the sinterability of hydroxyapatite

The sinterability of hydroxyapatite (HA) powder synthesized through a novel wet chemical method (HAp) and a wet mechanochemical method (HAwm) was investigated over a temperature range of 1000oC to 1400oC in terms of phase stability, bulk density, hardness and fracture toughness. The results indicated that the sinterability of HAp powder were significantly better than HAwm powder. Moreover, the XRD traces of HAwm sintered samples showed signs of decomposition into TTCP when sintered at 1300oC and above. Densification of ~98% of theoretical density was attained by HAp compacts at 1100oC while the HAwm compacts exhibited only ~96% of theoretical density even at 1350oC with no significant increase of density at 1400oC. The Vickers hardness of HAp showed increasing trend for temperature range of 1000oC to 1100oC with the compacts attaining HV of ~7 GPa at 1100oC. Subsequently, the hardness decreased with increasing sintering temperature though the value does not dropped below ~5 GPa. Similarly, HAwm compacts showed an increasing trend from 1000oC to 1300oC with the largest HV attained was ~4.57 GPa. Further increased in sintering temperature resulted in the decreased of Vicker’s hardness. Moreover, the HAp samples reached a maximum fracture toughness of ~0.9 MPam1/2 at 1050oC while the HAwm attained maximum KIc of only ~0.7 MPam1/2 at 1300oC

Effects of bismuth oxide on the properties of calcium phosphate bioceramics

The aim of this work is to study the phase stability and sinterability of bismuth oxide (Bi2O3) doped HA ranging from 0.05 wt% to 1 wt%. The green samples were sintered in air at temperature ranging from 1000oC to 1400oC. In this experiment, the results from XRD analysis revealed that the stability of HA phase was disrupted when addition of 0.3, 0.5 and 1.0 wt% Bi2O3 were used and when samples sintered above 1100oC, 1000oC and 950oC, respectively. In general, HA containing 0.5 wt% of Bi2O3 and when sintered at 1000oC was found to be beneficial in enhancing densification, Young’s modulus, Vickers hardness and fracture toughness. Throughout the sintering regime, the highest value of relative bulk density of 98.7% was obtained for 0.5 wt% Bi2O3-doped HA when sintered at 1000oC. A maximum Young’s modulus of 119.2 GPa was observed for 0.1 wt% Bi2O3-doped HA when sintered at 1150oC. Additionally, 0.5 wt% Bi2O3-doped HA was able to achieve highest hardness of 6.04 GPa and fracture toughness of 1.21 MPam1/2 at sintering temperature of 1000oC. Furthermore, the Young’s modulus of HA was found to vary linearly with bulk density

Using Principles of an Adaptation Framework to Adapt a Transdiagnostic Psychotherapy for People With HIV to Improve Mental Health and HIV Treatment Engagement: Focus Groups and Formative Research Study

BackgroundHIV treatment engagement is critical for people with HIV; however, behavioral health comorbidities and HIV-related stigma are key barriers to engagement. Treatments that address these barriers and can be readily implemented in HIV care settings are needed. ObjectiveWe presented the process for adapting transdiagnostic cognitive behavioral psychotherapy, the Common Elements Treatment Approach (CETA), for people with HIV receiving HIV treatment at a Southern US HIV clinic. Behavioral health targets included posttraumatic stress, depression, anxiety, substance use, and safety concerns (eg, suicidality). The adaptation also included ways to address HIV-related stigma and a component based on Life-Steps, a brief cognitive behavioral intervention to support patient HIV treatment engagement. MethodsWe applied principles of the Assessment, Decision, Administration, Production, Topical Experts, Integration, Training, Testing model, a framework for adapting evidence-based HIV interventions, and described our adaptation process, which included adapting the CETA manual based on expert input; conducting 3 focus groups, one with clinic social workers (n=3) and 2 with male (n=3) and female (n=4) patients to obtain stakeholder input for the adapted therapy; revising the manual according to this input; and training 2 counselors on the adapted protocol, including a workshop held over the internet followed by implementing the therapy with 3 clinic patients and receiving case-based consultation for them. For the focus groups, all clinic social workers were invited to participate, and patients were referred by clinic social workers if they were adults receiving services at the clinic and willing to provide written informed consent. Social worker focus group questions elicited reactions to the adapted therapy manual and content. Patient focus group questions elicited experiences with behavioral health conditions and HIV-related stigma and their impacts on HIV treatment engagement. Transcripts were reviewed by 3 team members to catalog participant commentary according to themes relevant to adapting CETA for people with HIV. Coauthors independently identified themes and met to discuss and reach a consensus on them. ResultsWe successfully used principles of the Assessment, Decision, Administration, Production, Topical Experts, Integration, Training, Testing framework to adapt CETA for people with HIV. The focus group with social workers indicated that the adapted therapy made conceptual sense and addressed common behavioral health concerns and practical and cognitive behavioral barriers to HIV treatment engagement. Key considerations for CETA for people with HIV obtained from social worker and patient focus groups were related to stigma, socioeconomic stress, and instability experienced by the clinic population and some patients’ substance use, which can thwart the stability needed to engage in care. ConclusionsThe resulting brief, manualized therapy is designed to help patients build skills that promote HIV treatment engagement and reduce symptoms of common behavioral health conditions that are known to thwart HIV treatment engagement